,,iii  #aacth ,,congress  #ast ,session 
,s4 ,,res4 #bea  ,,in ,,the ,,senate    
,,of ,,the ,,united ,,states  ,september
 #bc1 #bjac,mr4 ,sessions submitted the 
following resolution2 which was referred
 to the ,committee on ,health1          
,education1 ,labor1 and ,pensions       
,,resolution  ,expressing the sense of  
the ,senate that the ,united ,states    
,preventive ,services ,task ,force      
should reevaluate its recommendations   
against prostate-specific antigen-based 
screening for prostate cancer for men in
 all age groups in consultation with    
appropriate specialists4  ,whereas the  
,united ,states ,preventive ,services   
,task ,force 7referred to in this       
preamble as the ,,uspstf7 is an         
independent panel of primary care       
physicians1 not employed by the ,federal
 ,government1 who are experts in        
preventive and evidence-based medicine2 
,whereas the physicians on the ,,uspstf 
conduct scientific evidence reviews of a
 broad range of clinical health care    

preventive services and develop         
recommendations for primary care        
clinicians and health systems2 ,whereas 
prostate cancer is the second leading   
cause of cancer-related deaths of men in
 the ,united ,states2 ,whereas the      
,national ,cancer ,institute estimates  
that1 in #bjac1 #bch1eij men will be    
diagnosed with1 and #bi1gbj men will die
 of1 prostate cancer2 ,whereas the      
,national ,cancer ,institute estimates  
that #a in #f men will be diagnosed with
 prostate cancer during his lifetime2   
,whereas family history has been shown  
to be a risk factor for prostate cancer 
for men of all races and ethnicities1   
and men with a family history of        
prostate cancer are twice as likely to  
be diagnosed with the disease2 ,whereas 
the ,,uspstf acknowledges that prostate 
cancer is the most commonly diagnosed   
non-skin cancer for men in the ,united  
,states1 with a lifetime risk for       
diagnosis estimated at #ae4i percent2   
,whereas the ,,uspstf acknowledges that 

,african-,american men are twice as     
likely to die from prostate cancer than 
other men in the ,united ,states2       
,whereas the ,,uspstf does not have any 
members who are urologists1 a type of   
physician who specializes in diagnosing 
and treating patients with prostate     
cancer2 ,whereas the ,,uspstf does not  
have any members who are oncologists1 a 
type of physician who specializes in    
diagnosing and treating patients with   
cancer2 ,whereas the ,food and ,drug    
,administration first approved the      
prostate-specific antigen 7commonly     
referred to as ,,psa7 blood test for    
prostate cancer screening and diagnosis 
in #aiib and1 since that time1 the      
mortality rate due to prostate cancer   
has decreased by #dj percent2 ,whereas1 
in ,august #bjjh1 the ,,uspstf          
recommended against prostate-specific   
antigen-based screening for prostate    
cancer for men ages #ge and older1      
because the ,,uspstf determined that    
there was insufficient evidence to      

assess the balance of benefits and harms
 of prostate cancer screening in men    
younger than age #ge2 ,whereas1 in ,may 
#bjab1 the ,,uspstf issued a new        
recommendation1 to replace its #bjjh    
recommendation1 against                 
prostate-specific antigen-based         
screening for prostate cancer for men in
 all age groups1 because the ,,uspstf   
concluded that there is moderate-to-high
 certainty that the test has no net     
benefit1 or that the harms outweigh the 
benefits1 and suggested that this       
screening practice be discouraged2      
,whereas the ,may #bjab recommendation  
against screening applies to all men in 
the ,united ,states1 regardless of age2 
,whereas the ,may #bjab recommendation  
against screening applies to all men in 
the ,united ,states1 regardless of race1
 even though the ,,uspstf acknowledges  
that ,african-,american men have a      
substantially higher incidence rate for 
prostate cancer than ,white men have and
 more than twice the mortality rate from

 prostate cancer that ,white men have2  
,whereas the ,may #bjab recommendation  
against screening applies to all men in 
the ,united ,states1 even though the    
,,uspstf acknowledges that there is     
convincing evidence that                
prostate-specific antigen-based testing 
helps detect many cases of asymptomatic 
prostate cancer2 and ,whereas the       
,,uspstf acknowledges that clinical     
decisions regarding cancer screening    
involve multiple considerations and that
 clinicians should individualize        
decisionmaking to the specific patient  
or situation3 ,now1 therefore1 be it    
,that it is the sense of the ,senate    
that-- 7#a7 the ,united ,states         
,preventive ,services ,task ,force      
should-- 7,a7 reevaluate its            
recommendation against prostate-specific
 antigen-based screening for prostate   
cancer for men in all age groups2  7,b7 
seriously engage and consult with       
specialists1 including urologists and   
oncologists1 as it reevaluates its      

recommendation2 and  7,c7 identify areas
 for additional research and evaluation 
of methods of treatment of1 and         
screening procedures for1 prostate      
cancer2  7#b7 prostate cancer screening 
decisions should be made by each        
individual patient and his physician1   
taking into account the personal risk   
factors of the patient1 such as his     
overall health1 age1 race1 family       
history1 and life expectancy1 as well as
 his desire for eventual treatment if he
 is diagnosed with prostate cancer2 and 
7#c7 steps should be taken to raise     
awareness of1 and increase public       
knowledge about1 prostate cancer1 the   
benefits of early detection1 and the    
appropriateness of screening tests4